Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTICENTER STUDY OF TANEZUMAB ON PERIPHERAL NERVE FUNCTION IN PATIENTS WITH OSTEOARTHRITIS.

NCT00863772 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT00863772
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00863772 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTICENTER STUDY OF TANEZUMAB ON PERIPHERAL NERVE FUNCTION IN PATIENTS WITH OSTEOARTHRITIS.
Lead sponsor
Pfizer
Phase
Phase 3
Overall status
Terminated
Start date
May 18, 2009
Completion date
November 16, 2010
Enrollment
220 (actual)
Sites
97

Conditions

As the registry lists them; a condition with its own page is linked.

osteoarthritis